Neeuro is on mission to empower our minds to overcome brain health challenges through artificial intelligence and digital therapeutics.

Following the launch of our new Neurotech report, we are showcasing the dynamic and innovative companies we feel are driving this exciting space – our trailblazers. Over the coming weeks, we will be bringing you extracts from nine trailblazer profiles; each profile includes a flagship product deep dive which offers a forensic consideration of product development, efficacy, target market, channels to market, success factors, IP and funding.

Here’s the lowdown on Neeuro, and to read the full version of Neeuro’s profile (and much more besides!) in our HTML neurotech report please click here.

Neeuro is a global company, founded in 2013 in Singapore, which specialises in the utilisation of Brain-Computer Interface technology to maximise the potential of users’ neurological agility and fitness.

One of its main products, the Neeuro Senzeband, is a headband equipped with dry-electroencephalography (EEG) sensors that can capture brainwave signals non-invasively. The seven sensors are distributed over the prefrontal cortex and two on the side. The prefrontal cortex plays a central role in executive functions such as planning complex cognitive behaviour, personality expression, decision making, and moderating social behaviour.

The core technology, NeeuroOS, provides health care professionals, researchers, and third-party developers with an artificial intelligence (AI) driven platform that has the ability to analyse the brain signals and provide the user with meaningful insights and solutions to improve their brain function.

Neeuro’s vision is: “To be the enabler that empowers every human’s mind,” says Dr Alvin Chan, Co-Founder and CEO of Neeuro. “A Platform Ecosystem for Brain Computing that Powers Mental Health Solutions.”

Neeuro was founded by Eddie Chau, the current Chairman. As a serial entrepreneur, Eddie noticed the negative impact of poor sleep and high stress levels can have on people and became interested in finding a neurotechnology-based solution that could help users manage their mental health. He saw a great deal of potential that EEG data holds in this regard, but also its wider potential to help across all aspects of mental health. In addition, he saw that EEG data could be used to help the elderly, helping seniors suffering from stroke and cognitive decline, and in children with attention deficit hyperactivity disorder (ADHD). This is when Eddie Chau reached out to Alvin Chan, the co-founder, and CEO of Neeuro.

Alvin Chan was equally interested in the field and his engineering and computer science background contributed to his fascination with the amount of data, and therefore information that can be obtained from EEG data. Eddie and Alvin were motivated by personal experience as well, as both had family members and friends who had suffered from conditions such as dementia or ADHD and had a first-hand understanding of the impact that these conditions can have on people’s lives. With the rise of digital therapeutics which are, defined as “delivering evidence-based therapeutic interventions to patients that are driven by software to prevent, manage, or treat a medical disorder or disease”, they wanted to use these rising interests to specifically address disorders affecting the brain.

Neeuro’s major goal was to build neurotechnology products that can be home-based. With the end-user in mind, they understood that experiencing the full potential of the technology may be difficult for busy parents who cannot afford to take three days off to see a therapist or for the elderly who may also struggle to attend appointments due to their symptoms or do not have the nearby care to support them. Neeuro aims to bring solutions to solve these challenges within the home itself.

The importance of home-based solutions became ever more apparent to the company in the light of the recent COVID pandemic, where access to care became difficult and the founders of Neeuro wanted to ensure that care delivered through their technology would not overburden the hospitals further. To make its products home and user friendly, they had to be easy and fun to use which is why Neeuro’s solution is to train the brain centres around gamification.

Neeuro stands out from its competitors by ensuring its solutions are always based on strong clinical evidence, long before they even make it onto the market and are commercialised. Its current products are backed by 10 years of work and 10 years of scientific publications. Furthermore, Neeuro’s extensive portfolio and an array of offerings empower digital therapeutics and brain fitness solutions are backed with clinical validated research by the Agency for Science, Technology and Research (A*STAR), an institute widely known as being at the forefront of Singapore’s research endeavours.

In addition, Neeuro is working closely with neuroscientists as well as clinicians and the medical community, providing Neeuro with a strong vote of confidence in the potential of its technology.

In the next 5 years, Neeuro hopes to secure future partnerships with other solution providers integrating the Neeuro technology and algorithms into their products. Although its technology has potential across many different target markets, the major focus in the coming years is for Neeuro to grow its ADHD and senior/ageing market as there is a large increase in children being diagnosed with ADHD or inattentive symptoms and a rapidly ageing population. Their aim for both markets is to expand beyond the Singapore market and reach APAC, China, Europe and US.

Click here to read our Neurotech report absolutely FREE.